This bill establishes a comprehensive regulatory framework for hemp-derived cannabinoids in New Jersey, primarily overseen by the Cannabis Regulatory Commission. It mandates the registration and regulation of these products, particularly addressing the rise of psychoactive substances like Delta-8-THC that may exceed legal cannabinoid levels. The legislation introduces new definitions for terms related to cannabinoids and expands the commission's jurisdiction to include the regulation of hemp-derived products. It outlines the commission's responsibilities, including the adoption of rules for registration, testing, labeling, and compliance, as well as the establishment of security and age restrictions to prevent sales to minors.

Additionally, the bill requires that all hemp-derived cannabinoid products undergo testing by licensed laboratories, ensuring adherence to safety standards. It specifies that laboratories must maintain labor peace agreements and conduct background checks for licensure applicants. The commission is also tasked with studying the effects of these cannabinoids on driving and reporting findings to enhance public safety. Retailers selling hemp-derived products prior to the bill's enactment are given a one-year compliance period. Overall, the legislation aims to ensure consumer safety, promote responsible business practices, and provide a structured approach to the regulation of hemp-derived cannabinoid products in the state.

Statutes affected:
Introduced: 24:6I-34, 24:6I-17, 24:6I-18